The National Institute for Health and Care Excellence (NICE) has published landmark guidance for treating Primary Myelofibrosis with Osteosclerosis (PMOS), a rare and aggressive blood cancer that affects fewer than 500 people in the UK each year. For these patients, who are often left feeling isolated due to the lack of understanding about their condition, this new guidance offers hope for improved diagnosis, monitoring, and treatment.
PMOS is a chronic myeloid neoplasm characterised by the abnormal proliferation of bone marrow cells, leading to fibrosis (scarring) and hardening of the bone marrow. This can severely impair the body's ability to produce healthy blood cells, resulting in anaemia, fatigue, an enlarged spleen, and an increased risk of infections and bleeding. The NHS reports that each year there are approximately 440 new cases of PMOS in England alone.
The NICE guidance is expected to address the inconsistent treatment pathways for PMOS patients by providing clear recommendations for healthcare professionals. While specific details of the recommended treatments have not yet been disclosed, the guidance typically covers a range of options, from watchful waiting and symptom management to drug therapies and, in some cases, stem cell transplantation. The focus will be on improving quality of life, managing symptoms, and potentially extending life expectancy for PMOS patients.
This move by NICE aligns with its mandate to provide evidence-based guidance that improves health and social care outcomes. Historically, rare diseases have faced challenges in securing dedicated guidelines due to the limited patient population and research data. The issuance of this specific guidance for PMOS underscores the growing commitment to ensuring that even those with less common conditions benefit from structured and effective treatment strategies within the NHS.
For the NHS, the guidance will facilitate better resource allocation and training, ensuring that specialist centres and haematology departments are equipped to offer the best possible care for PMOS patients. It will also support clinical commissioning groups (CCGs) in making informed decisions about funding treatments, based on nationally recognised best practices. This is a positive step towards reducing geographical variations in access to high-quality care for this challenging condition.